MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Stopped Funding not available, study did not open to accrual and will not open in future

Conditions

• Metastatic Breast Cancer

Interventions

• DRUG: MSK-2206
• DRUG: Exemestane
• DRUG: Goserelin

Sponsor

Vanderbilt-Ingram Cancer Center